G whiz! The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as ...

Happening Friday at 11 a.m., the policy briefing will focus on the future of the Affordable Care Act, featuring a discussion ...

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Guy Fieri has visited Georgia many times on Food Network's "Triple D." Here's a list of the Savannah-area hot spots the Mayor ...

Here's chef and Season 16's Sweet and Savory Duos winner Russell LaCasce's behind-the-scenes take on what contestants ...

Retatrutide, an experimental diabetes drug, reduced A1C levels by 2 percent and body weight by 17 percent in a new late-stage trial. Unlike rival medications, which target one or two hormone receptors ...

At the end of a seemingly ubiquitous commercial for telehealth company Ro, a characteristically flabbergasted Charles Barkley speaks for us all when he remarks, “Wait, you’re telling me they have a ...

March 19 (Reuters) - Eli Lilly (LLY.N), opens new tab's next-generation obesity drug showed a significant reduction in blood sugar levels and weight in a late-stage trial, the company said on Thursday ...

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

A look at the top fantasy prospects who can help fantasy rosters in 2026 and beyond ...